Support Centre
31 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomised trial of the cost-effectiveness of a program of screening and intensive multifactorial intervention for type 2 diabetes in primary care
DOI 10.1186/ISRCTN86769081
ClinicalTrials.gov identifier NCT00237549
EudraCT number
Public title A randomised trial of the cost-effectiveness of a program of screening and intensive multifactorial intervention for type 2 diabetes in primary care
Scientific title
Acronym The ADDITION Study
Serial number at source 061895
Study hypothesis 1. To evaluate the effectiveness and cost (economic and psychological) of a program of screening and intensive multifactorial intervention for type two diabetes in primary care.
2. To measure the effect of a multifactorial intervention for people with screen-detected type two diabetes aged 40 to 69 years on modelled mortality and cardiovascular risk.
3. To assess the psychological and health service costs of screening for type two diabetes.
4. To provide the National Screening Committee with timely evidence to inform the decision on whether screening for type two diabetes should become part of health policy in the United Kingdom.

On 27/10/2014 the anticipated end date was changed from 31/12/2010 to 01/12/2015.
Lay summary Background and study aims
Type 2 diabetes is increasingly common and responsible for significant costs to patients and the health service, mainly through increasing the risk of heart attacks and strokes (cardiovascular disease). At the outset diabetes tends not to cause any symptoms and so people can have the condition for many years without realising it. Indeed, up to half of all people with diabetes remain undiagnosed. One possible strategy to deal with this would be to screen the population with a simple blood test. However, it is only worthwhile screening the population if treatment is effective early in the course of the disease. While there have been many studies among people with longstanding diabetes that have helped to inform treatment guidelines, there have been no previous studies evaluating treatment for people with diabetes detected by screening. The ADDITION study aims to see if helping patients with screen-detected diabetes and general practice teams to intensively treat risk factors for cardiovascular disease (CVD) in the first 5 years after diagnosis will reduce the risk of CVD. The study results will inform guidelines for initial treatment of diabetes and policy decisions about screening.

Who can participate?
This study has now finished recruiting. Participants were aged between 40-64 years at the time of recruitment (2000 to 2006) and identified as having diabetes through the studyís screening programme. This involved an initial finger-prick blood sugar (glucose) test in general practice. If this was positive, participants were invited to return fasted for a second finger-prick test, followed if positive by a glucose tolerance test to check that the person did have diabetes.

What does the study involve?
GP practices taking part in the study were randomly allocated to one of two groups: a control group and a treatment group. Participants in the study did not know which group their practice was in. GP practices in the control group were asked to follow routine national guidelines for the treatment of diabetes. GP practices in the treatment group received education and guidelines concerning treatment of diabetes and CVD risk factors. This included treatments such as starting medications (to lower levels of glucose, cholesterol and blood pressure) or giving lifestyle advice (about diet and physical activity) to patients with screen-detected diabetes. Patients were provided with educational materials. All participants were invited to a baseline clinic appointment (at the point that they were tested for diabetes). This involved collecting information on the participantsí overall health (such as blood pressure, weight and taking a history of other medications they were taking) as well as asking them to complete questionnaires on lifestyle (such as their diet and amount of exercise they took). We followed participants up 1 and 5 years later and took all the same measures again. This allowed us to see if there were any health differences between the people who had received routine care and those who had received intensive treatment. We also looked at their medical records to see if they had experienced any CVD events. This included whether they had had a heart attack, stroke or amputation. We now plan to do a 10-year follow-up. This time, instead of inviting people to clinic, we will collect the same information again but from the participantís medical records and by sending individuals a questionnaire in the post.

What are the possible benefits and risks of participating?
All participants enrolled in the study received a test to check if they had diabetes. They also received a check up from the study team after 1 and 5 years of taking part in the study. This included blood tests, such as blood glucose measure and liver function test; weight measurements, and blood pressure. There were limited risks to taking part in the study as all participants continued to receive routine care from their GPs.

Where is the study run from?
The study was run from two centres in the UK: the MRC Epidemiology Unit in Cambridge, and the Leicester Diabetes Centre. We also worked with researchers in the Netherlands and Denmark who were collecting the same information from patients there.

When is the study starting and how long is it expected to run for?
The study started in June 2001 and finished recruiting in March 2006. The study is now about to enter a 10-year follow-up phase which we will be complete in December 2015.

Who is funding the study?
The study has been funded by the Medical Research Council, NIHR Health Technology Assessment Programme, National Health Service R&D, and the National Institute for Health Research (UK).

Who is the main contact?
Gwen Brierley
Tel: +44 (0)1223 746869
Ethics approval 1. ADDITION: Eastern MREC, ref: 02/5/54
2. ADDITION 5 Year: Cambridgeshire 1 REC, ref: 08/H0304/67
3. ADDITION 10 Year: East of England - Cambridge East REC, ref: 14/EE/1129
Study design Pragmatic randomised parallel-group design
Countries of recruitment Denmark, Netherlands, United Kingdom
Disease/condition/study domain Type 2 diabetes
Participants - inclusion criteria 1. Aged 40 to 69 years
2. Without known diabetes but with a diabetes risk score in the top 30%
Participants - exclusion criteria 1. Already have diabetes
2. Are pregnant or lactating
3. Have a psychotic illness
4. Have an illness with a prognosis of less than one year
Anticipated start date 01/06/2001
Anticipated end date 01/12/2015
Status of trial Ongoing
Patient information material
Target number of participants Recruitment completed on 31/03/2006
Interventions In a pragmatic, parallel-group design, general practices recruited to the study in the local area are randomly allocated centrally to control, to screening for type two diabetes followed by routine care of screen-detected cases according to national recommendations, and to screening followed by intensive multifactorial intervention. A minimisation procedure is used to balance the baseline practice variables.

The previous sponsor for this trial (up to 27/10/2014) was:
CamStrad (Cambridgeshire Support Team - Research and Development) (UK)
Nightingale Court
Ida Darwin
United Kingdom
Primary outcome measure(s) Risk models for mortality and cardiovascular events, specific to people with diabetes, based on age, gender, blood pressure, Body Mass Index (BMI), smoking, previous myocardial infarction, total cholesterol, triglyceride, High Density Lipoprotein (HDL), HbA1c and albuminuria.
Secondary outcome measure(s) No secondary outcome measures
Sources of funding The Wellcome Trust (UK) (grant ref: 061895)
Trial website http://www.addition.au.dk/
Publications 2009 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/19435491
2012 results in: http://www.ncbi.nlm.nih.gov/pubmed/23040422
Contact name Dr  Simon  Griffin
  Address MRC Epidemiology Unit
Strangeways Research Laboratory
Worts Causeway
  City/town Cambridge
  Zip/Postcode CB1 8RN
  Country United Kingdom
  Tel +44 (0)1223 330315
  Fax +44 (0)1223 740050
  Email simon.griffin@mrc-epid.cam.ac.uk
Sponsor University of Cambridge (UK)
  Address c/o Dr Joanne Martindale
Research Operations Office
School of Clinical Medicine
Box 111
Addenbrooke's Hospital
Hills Road
  City/town Cambridge
  Zip/Postcode CB2 0SP
  Country United Kingdom
  Tel +44 (0)1223 333543
  Email croenquiries@admin.cam.ac.uk
Date applied 15/12/2006
Last edited 27/10/2014
Date ISRCTN assigned 15/12/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.